FDA CTP Releases Comprehensive Strategic Plan for Next 5 Years

Regulations by 2FIRSTS.ai
Dec.19.2023
FDA CTP Releases Comprehensive Strategic Plan for Next 5 Years
FDA's Center for Tobacco Products (CTP) released its comprehensive strategic plan, aiming to reduce the negative health impacts of tobacco use.

On December 18th, according to an announcement on the official website of the United States Food and Drug Administration (FDA), Brian King, the Director of the FDA Center for Tobacco Products (CTP), released a statement outlining the center's comprehensive strategic plan.

 

Previously, CTP responded to the evaluation conducted by the independent expert group organized by the Reagan-Udall Foundation, announcing the initiation of a brand new five-year strategic plan, which will be unveiled by the end of the year. Since then, the center has focused on the new strategic plan as its core task, actively seeking feedback from external stakeholders through public opinion surveys and hearings, in order to enhance its planning capabilities.

 

CTP's new strategic plan was officially unveiled today. The plan outlines how the organization will operate and manage its staff in the next five years. This strategic plan marks a new chapter for CTP, building upon the solid foundation it has established since its inception in 2009. Guided by this plan, CTP aims to reduce the adverse health impacts caused by tobacco use. This includes ensuring the regulated functioning of the market, preventing the initiation of tobacco use among the public, promoting smoking cessation among tobacco users, and minimizing the harms associated with tobacco product use.

 

During the development of this strategic plan, CTP also updated its vision and mission to accurately reflect its nature of work and guide future activities. These modifications emphasize the importance of CTP's public health priorities and advancing health equity. The strategic plan sets out five objectives, ten outcomes, and proposes several corresponding goals.

 

The CTP plans to achieve these goals and outcomes by issuing influential regulations, utilizing scientific methods for application review, implementing timely and impactful compliance and enforcement strategies, and educating the public about the risks associated with tobacco products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands Reports Q1 2026 Net Sales of $124.3 Million as Modern Oral Net Sales Rise 133%
Turning Point Brands reported first-quarter 2026 results on May 7, covering the period ended March 31, 2026. Total consolidated net sales were $124.3 million, up 16.8% year on year. Gross profit was $68.3 million, up 14.6%, while net income fell 19.0% to $11.7 million. Adjusted EBITDA declined 6.5% to $25.9 million.
May.08 by 2FIRSTS.ai
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal and Other Countries Submit Objections in Brussels Over UK Smoke-Free Generation Bill
Portugal is among the countries opposing the UK Tobacco and Vapes Bill, which would ban tobacco sales to people born on or after Jan. 1, 2009. According to the report, Portugal, Croatia, the Czech Republic, Greece, Italy, Slovakia and Romania have submitted reasoned opinions and formal observations to Brussels, arguing that the bill breaches post-Brexit arrangements including the Windsor Framework.
Apr.24 by 2FIRSTS.ai
UK Vaping Products Duty to Raise £565 Million by 2030/31
UK Vaping Products Duty to Raise £565 Million by 2030/31
The UK will introduce Vaping Products Duty on all vaping liquids from October 1, 2026, with government revenue forecast to rise from £135 million in 2026/27 to £565 million by 2030/31.
Jun.18
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands Explains What the UK Tobacco and Vapes Act 2026 Means for Retailers
Imperial Brands has outlined what the newly approved UK Tobacco and Vapes Act 2026 means for retailers. The legislation received Royal Assent on April 29, 2026, and gives the Government powers to extend tobacco-style regulation to a wider range of products, including vaping products, heated tobacco, nicotine pouches and cigarette papers. Imperial Brands emphasized that most measures will be introduced in phases rather than taking effect immediately.
May.11 by 2FIRSTS.ai
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
AP Questions FDA Rationale as Glas Fruit-Flavored Vapes Won Authorization Without Added Cessation Benefit
The U.S. Food and Drug Administration (FDA) recently authorized two fruit-flavored vaping products from Glas, but a newly released agency memo shows the products did not demonstrate greater smoking-cessation benefits than tobacco-flavored e-cigarettes. The Associated Press said the findings are likely to raise further questions about the FDA’s regulatory rationale and standards for flavored vaping products.
Jun.12
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
BAT Shares Surge Nearly 6% as FDA Policy Shift Eases Pressure on Vuse and Velo
British American Tobacco (BAT) shares rose sharply on May 12 after the U.S. Food and Drug Administration signaled it would deprioritize enforcement against certain unauthorized e-cigarette and nicotine pouch products with accepted premarket applications. Investors viewed the move as favoring established players such as BAT’s Vuse and Velo brands.
BAT
May.13